Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 312 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypothalamic-pituitary Disorders Clear all
Completed Not applicable Interventional

Randomized Study of Growth Hormone on Bone Mineral Density in Patients With Adult Onset Growth Hormone Deficiency

NCT00006394
View directory record Official record
Conditions
Osteoporosis, Growth Hormone Deficiency
Interventions
growth hormone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
7
States / cities
Boston, Massachusetts • Rochester, Minnesota • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 7:34 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

International PPB/DICER1 Registry

NCT03382158
View directory record Official record
Conditions
Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor, DICER1 Syndrome, Cystic Nephroma, Wilms Tumor, Pineoblastoma, Renal Sarcoma, Nodular Hyperplasia of Thyroid, Nasal Chondromesenchymal Hamartoma, Ciliary Body Medulloepithelioma, Neuroblastoma, Pituitary Cancer, Embryonal Rhabdomyosarcoma, Ovarian Sarcoma, Gynandroblastoma, Thyroid Carcinoma, Embryonal Rhabdomyosarcoma of Vagina (Diagnosis), Embryonal Rhabdomyosarcoma of Uterus (Diagnosis), Embryonal Rhabdomyosarcoma of Cervix
Interventions
Not listed
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
0 Minutes to 100 Years
Enrollment
3,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2035
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 21, 2026, 7:34 PM EDT
Recruiting Early Phase 1 Interventional

FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease

NCT07460232
View directory record Official record
Conditions
Cushing Disease, Pituitary Adenoma
Interventions
Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

NCT02685709
View directory record Official record
Conditions
Acromegaly
Interventions
Octreotide capsules
Drug
Lead sponsor
Chiasma, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 21, 2026, 7:34 PM EDT
Completed Phase 4 Interventional Results available

Growth Hormone and Endothelial Function in Children

NCT00373386
View directory record Official record
Conditions
Growth Hormone Deficiency, Panhypopituitarism, Short Stature
Interventions
growth hormone
Drug
Lead sponsor
Ohio State University
Other
Eligibility
8 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 21, 2026, 7:34 PM EDT
Completed No phase listed Observational

A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly

NCT06253897
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor, Acromegaly
Interventions
Not listed
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 21, 2026, 7:34 PM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 21, 2026, 7:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Racial Discrimination and Stress Response

NCT05820659
View directory record Official record
Conditions
Stress Reaction; Acute
Interventions
peer rejection task, conversation about peer rejection, and impossible puzzle task
Behavioral
Lead sponsor
Western Kentucky University
Other
Eligibility
9 Years to 99 Years
Enrollment
178 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bowling Green, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 21, 2026, 7:34 PM EDT
Completed No phase listed Observational

Pelvic Pain in Women With Endometriosis

NCT00073801
View directory record Official record
Conditions
Endometriosis, Chronic Pelvic Pain
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 7:34 PM EDT
Terminated Phase 3 Interventional Results available

Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study

NCT01237340
View directory record Official record
Conditions
Growth Hormone Deficiency (GHD)
Interventions
Saizen®
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
US Medical Information, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2013 · Synced Oct 21, 2026, 7:34 PM EDT
Completed Phase 1 Interventional

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

NCT00006368
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
Interventions
yttrium Y 90-edotreotide
Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 21, 2026, 7:34 PM EDT
Recruiting No phase listed Observational

A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin

NCT05775523
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
No intervention
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
1 Year to 18 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
27
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 21, 2026, 7:34 PM EDT
Not listed Phase 3 Interventional

Treatment of Children With Insufficient Secretion of Growth Hormone

NCT00271518
View directory record Official record
Conditions
Growth Hormone Deficiency (GHD)
Interventions
growth hormone (somatropin)
Drug
Lead sponsor
LG Life Sciences
Industry
Eligibility
3 Years to 11 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Oct 21, 2026, 7:34 PM EDT
Completed Phase 4 Interventional Results available

Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors

NCT02351700
View directory record Official record
Conditions
Pituitary Tumor, Pain
Interventions
IV Caldolor, IV Placebo
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 79 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 21, 2026, 7:34 PM EDT
Terminated Phase 2 Interventional Results available

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

NCT00958841
View directory record Official record
Conditions
Pancreatic Neoplasm, Pituitary Neoplasm, Nelson Syndrome, Ectopic ACTH Syndrome
Interventions
pasireotide LAR
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 21, 2026, 7:34 PM EDT
Terminated Phase 3 Interventional

A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

NCT03145831
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Somavaratan
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
3 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 21, 2026, 7:34 PM EDT
Recruiting Phase 3 Interventional

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

NCT06760546
View directory record Official record
Conditions
Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia, Childhood-onset Combined Pituitary Hormone Deficiency, Pituitary Stalk Interruption Syndrome
Interventions
Setmelanotide, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
4 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 21, 2026, 7:34 PM EDT
Withdrawn Phase 2 Interventional

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

NCT04106843
View directory record Official record
Conditions
Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Metastatic Parathyroid Gland Carcinoma, Pituitary Gland Carcinoma, Somatostatin Receptor Positive, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage IV Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma
Interventions
Lutetium Lu 177 Dotatate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 21, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

Versartis International Trial in Adults With Long-Acting Growth Hormone

NCT02526420
View directory record Official record
Conditions
Adult Growth Hormone Deficiency
Interventions
somavaratan
Drug
Lead sponsor
Versartis Inc.
Industry
Eligibility
23 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Escondido, California • Laguna Hills, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 21, 2026, 7:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

NCT01137682
View directory record Official record
Conditions
Acromegaly
Interventions
Pasireotide, octreotide LAR 30mg, lanreotide ATG 120mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
4
States / cities
Ann Arbor, Michigan • Portland, Oregon • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 21, 2026, 7:34 PM EDT
Completed No phase listed Observational

Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors

NCT01568359
View directory record Official record
Conditions
Acromegaly, Nonfunctioning Pituitary Tumor
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 21, 2026, 7:34 PM EDT
Recruiting Not applicable Interventional

DDAVP for Pituitary Adenoma

NCT04569591
View directory record Official record
Conditions
Cushing's Disease, Pituitary Adenoma
Interventions
Desmopressin acetate
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
8 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 21, 2026, 7:34 PM EDT
Completed Early Phase 1 Interventional

Effects of Hormone Stimulation on Brain Scans for Cushing s Disease

NCT01459237
View directory record Official record
Conditions
Pituitary Neoplasm
Interventions
Acthrel
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
8 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 21, 2026, 7:34 PM EDT
Terminated No phase listed Observational

Proton Radiation Therapy for Pituitary Adenoma

NCT00798057
View directory record Official record
Conditions
Pituitary Adenoma
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Oct 21, 2026, 7:34 PM EDT